Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anticancer fibroblast growth factor receptor 2 or 3 or 4 inhibitor - Applied Pharmaceutical Science

Next Previous
X
Search
Drug Profile

Anticancer fibroblast growth factor receptor 2 or 3 or 4 inhibitor - Applied Pharmaceutical Science

Alternative Names: Anticancer FGFR2 or FGFR3 or FGFR4 inhibitor - Applied Pharmaceutical Science; FGFR2 or FGFR3 or FGFR4 inhibitor - Applied Pharmaceutical Science

Latest Information Update: 03 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Applied Pharmaceutical Science
  • Class Antineoplastics
  • Mechanism of Action Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 27 Jan 2022 Anticancer fibroblast growth factor receptor 2 or 3 or 4 inhibitor - Applied Pharmaceutical Science is available for licensing in World as of 27 Jan 2022. https://www.apspharm.com/hezuolianmeng/
  • 27 Jan 2022 Preclinical trials in Solid tumours in China (unspecified route) (Applied Pharmaceutical Science website, January 2022)
  • 27 Jan 2022 Preclinical trials in Solid tumours in USA (unspecified route) (Applied Pharmaceutical Science website, January 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top